Core Insights - Hims & Hers Health, Inc. (HIMS) operates a technology-driven digital health platform that provides personalized care through software, data, and virtual clinical workflows [1][2] - The company has launched new services, including Labs for biomarker tracking and expanded offerings in menopause and men's health [2][7] - Recent acquisitions, including Livewell and YourBio Health, enhance HIMS' diagnostic capabilities and geographic reach [3][7] Company Developments - Hims & Hers has introduced Labs, allowing customers to monitor biomarkers and receive personalized action plans from doctors [2][7] - The company has expanded into menopause care and launched branded testosterone treatments with at-home testing options [2][7] - The acquisition of Livewell marks HIMS' entry into Canada, while YourBio Health integrates blood-sampling technology into its platform [3][7] Financial Performance - Hims & Hers shares have increased by 56.7% year to date, outperforming the industry growth of 8.1% [6] - The forward 12-month price-to-sales ratio for HIMS is 3.2X, lower than the industry average of 4.9X but higher than its three-year median of 2.6X [9] - The Zacks Consensus Estimate for HIMS' 2025 earnings per share indicates a 77.8% improvement from 2024 [9]